Verastem Inc - Real-time stock metrics, market data, and comprehensive analysis
Fetching stock data...
Verastem Oncology is a biopharmaceutical company committed to developing and commercializing new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers. Verastem markets AVMAPKI™ FAKZYNJA™ CO-PACK in the U.S. Our pipeline is focused on novel small molecule drugs that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, including RAF/MEK inhibition, FAK inhibition, and KRAS G12D inhibition.
No news available
Have a question or want to work together? Fill out the form below and we’ll get back to you as soon as possible.
